Territories, MacrilenTM, Aeterna Zentaris' item for use in the evaluation of adult growth-hormone deficiency , for which a fresh Drug Application is currently under review by the FDA, with a Prescription Drug User Fee Action time of November 5, 2014. Related StoriesViralytics enters into scientific trial collaboration agreement with MSDCrucial modification in single DNA bottom predisposes children to intense form of cancerNew RNA test of blood platelets can be used to detect location of cancerAs component of its commercial strategy, Aeterna Zentaris anticipates using approximately 20 product sales representatives to cover its assigned U.S.Daniel Barocas, an assistant professor of urologic medical procedures at Vanderbilt University, in Nashville, Tenn. They are low-risk cancers that most men will not die of, and the treatment could be more harmful compared to the cancer, he explained. Compared to that level, the guideline had a beneficial effect, Barocas said. On the negative part, we seem to be missing intermediate and high-risk cancers in men who would be eligible for treatment, he stated. Those are missed opportunities to identify disease and address it. The report will be published in the December problem of the Journal of Urology.